



NEWS RELEASE

BIOSYENT RELEASES RESULTS FOR THIRD QUARTER AND FIRST NINE MONTHS OF 2018

FOR IMMEDIATE RELEASE

NOVEMBER 21, 2018

TORONTO, ONTARIO (November 21, 2018)

BioSyent Inc. ("BioSyent", TSX Venture: RX) released today a summary of its financial results for the three and nine months ended September 30, 2018. Key highlights include:

- Third quarter (Q3) 2018 Net Revenues of \$5,259,493 decreased by 3% versus Q3 2017
- First nine months (YTD) 2018 Net Revenues of \$15,616,063 increased by 5% versus YTD 2017
- Q3 2018 Canadian Pharmaceutical Net Revenues of \$4,709,409 increased by 11% versus Q3 2017 and International Pharmaceutical Net Revenues of \$281,801 decreased by 51% versus Q3 2017
- YTD 2018 Canadian Pharmaceutical Net Revenues of \$13,506,185 increased by 13% versus YTD 2017 and International Pharmaceutical Net Revenues of \$1,359,125 decreased by 15% versus YTD 2017
- Q3 2018 EBITDA¹ of \$1,729,585 decreased by 1% versus Q3 2017
- YTD 2018 EBITDA¹ of \$5,295,990 increased by 7% versus YTD 2017
- Q3 2018 Net Income After Tax (NIAT) of \$1,270,613 decreased by 2% versus Q3 2017
- YTD 2018 NIAT of \$4,033,976 increased by 8% versus YTD 2017
- Q3 2018 NIAT percentage to Net Revenues of 24% compares to 24% in Q3 2017
- YTD 2018 NIAT percentage to Net Revenues of 26% compares to 25% in YTD 2017
- Q3 2018 Fully Diluted EPS of \$0.09 compares to \$0.09 Fully Diluted EPS for Q3 2017
- YTD 2018 Fully Diluted EPS of \$0.28 was \$0.02 higher than YTD 2017 Fully Diluted EPS of \$0.26
- Fully Diluted EPS for the Trailing Twelve Months ended September 30, 2018 was \$0.38 as compared to \$0.34 for the Trailing Twelve Months ended September 30, 2017
- As at September 30, 2018, the Company had cash, cash equivalents, and short term investments totalling \$22,604,792 as compared to \$19,338,435 as at December 31, 2017 – a 17% increase
- Total Shareholders' Equity increased by 20% from \$22,212,927 at December 31, 2017 to \$26,554,310 at September 30, 2018
- Return on Equity for the Trailing Twelve Months ended September 30, 2018 was 24%

"Q3 2018 marked BioSyent's 33rd consecutive profitable quarter," noted René Goehrums, President and CEO of BioSyent. "Our Canadian pharmaceutical business delivered 11% growth during the quarter, with growth generated from across our product portfolio. Our International pharmaceutical business faced some challenges due to trade restrictions in a particular export market which resulted in reductions in the number and size of planned international FeraMAX[®] shipments during the quarter. While we don't expect these challenges to persist over the long-term, we anticipate further instability in international FeraMAX[®] sales in the near-term. Growth in our Legacy Business during the quarter also declined when compared with a particularly strong Q3 2017. Although there was an overall decline of 3% in total Company sales for the third quarter of 2018 versus Q3 2017, we are nevertheless encouraged by continued growth in our core pharmaceutical business in Canada.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

The CEO's presentation on the Q3 2018 Results is available at the following link: www.biosyent.com/q3-18/.

The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2018 and 2017 will be posted on www.sedar.com on November 21, 2018.

For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,521,154 common shares issued and outstanding.

BioSyent Inc. Interim Unaudited Condensed Consolidated Statements of Comprehensive Income

In Canadian Dollars	Q3 2018	Q3 2017	% Change	YTD 2018	YTD 2017	% Change
Net Revenues	5,259,493	5,403,600	-3%	15,616,063	14,861,267	5%
Cost Of Goods Sold	1,155,171	1,210,062	-5%	3,542,971	3,397,110	4%
Gross Profit	4,104,322	4,193,538	-2%	12,073,092	11,464,157	5%
Operating Expenses and Finance Income	2,337,926	2,478,475	-6%	6,694,457	6,563,440	2%
Net Income Before Tax	1,766,396	1,715,063	3%	5,378,635	4,900,717	10%
Tax (including Deferred Tax)	495,783	420,488	18%	1,344,659	1,151,668	17%
Net Income After Tax	1,270,613	1,294,575	-2%	4,033,976	3,749,049	8%
Net Income After Tax % to Net Revenues	24%	24%		26%	25%	
EBITDA	1,729,585	1,735,580	-1%	5,295,990	4,949,818	7%
EBITDA % to Net Revenues	33%	32%		34%	33%	

- EBITDA** – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

BioSyent Inc.

Interim Unaudited Condensed Consolidated Statements of Financial Position

AS AT	September 30, 2018	December 31, 2017	% Change
ASSETS			
Trade and other receivables	\$ 2,297,192	\$ 2,236,695	3%
Inventory	1,340,010	908,825	47%
Prepaid expenses and deposits	470,760	147,326	220%
Income tax recoverable	-	71,924	-100%
Derivative asset	37,884	-	100%
Cash, cash equivalents and short-term investments	22,604,792	19,338,435	17%
Current Assets	26,750,638	22,703,205	18%
Equipment	256,769	290,926	-12%
Intangible assets	1,925,878	1,670,210	15%
Loans receivable	396,806	393,860	1%
Deferred tax asset	42,518	46,647	-9%
TOTAL NON CURRENT ASSETS	2,621,971	2,401,643	9%
TOTAL ASSETS	\$ 29,372,609	\$ 25,104,848	17%
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities	\$ 2,461,743	\$ 2,615,594	-6%
Deferred tax liability	356,556	276,327	29%
Long term debt	-	-	0%
Total Equity	26,554,310	22,212,927	20%
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 29,372,609	\$ 25,104,848	17%

For further information please contact:

Mr. René C. Goehrum
 President and CEO
 BioSyent Inc.
 Tel: (905) 206-0013
 E-Mail: investors@biosyent.com
 Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.